Cardiovascular

• Resistant Hypertension / Uncontrolled Blood Pressure - Addressing the need for novel pharmacotherapies/mechanisms of actions (MOA) for patients with Resistant Hypertension/Uncontrolled Blood Pressure. This includes the needs of specific subgroups such as Black and Elderly/Frail patients and those with comorbid diseases that include Chronic Kidney Disease, Obesity and Diabetes for the 2023 calendar year.
   
• Thrombosis – Addressing oral anticoagulation for prevention of stroke in Atrial Fibrillation, Treatment of DVT or PE, Prevention of long term Recurrence of VTE, Prevention of VTE in Medically Ill, reduction of thrombotic events in CAD/PAD or in patients with PAD after revascularization and treatment of VTE or prevention VTE recurrence in pediatric patients or thromboprophylaxis for pediatric patients after Fontan procedure.  This includes therapy need for specific subgroups such as Black, Elderly/Frail, or those with comorbid diseases including renal dysfunction, obesity, or diabetes for the 2023 calendar year.

Please click here to view the certificate of separation.
 

For general questions please email [email protected].

Click here to submit an Independent Medical Education Grant